Show simple item record

dc.contributor.authorBeran, Roy G
dc.contributor.authorSathiyaseelan, Sandiya
dc.contributor.authorDevereux, John
dc.date.accessioned2019-07-02T23:02:53Z
dc.date.available2019-07-02T23:02:53Z
dc.date.issued2018
dc.identifier.issn0723-1393
dc.identifier.urihttp://hdl.handle.net/10072/384478
dc.description.abstractIntroduction Progressive Multifocal Leukoencephaly (PML) is an opportunistic central nervous system infection with John Cunningham Virus (JCV) that is potentially fatal or severely debilitating. Most neurologists think the risk of PML with JCV positive patients, treated with either fingolimod or dimethyl fumarate is so low that they avoid testing or discussing it with patients. Patients and Methods Patients offered testing for JCV readily accepted the option, despite being advised that most neurologists would not order the test and would take little note of the result. Results The 4 patients who were positive for testing for JCV all opted to change treatment to a perceived less efficacious medication, which has no reported cases of PML associated with it. Discussion The Australian case of Rogers vs Whitaker set the benchmark for material risk consideration in which such risk should be respected when doctors discuss treatment with patients. In Rogers the risk was 1/14,800 while for fingolimod the risk is 1/10,000 if JCV positive and less so for dimethyl fumarate. This report confirms that even these low risks directly influence patient choices and leave clinicians potentially liable in negligence if they do not inform patients of the risk of developing PML.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherHeinOnline
dc.publisher.urihttps://heinonline.org/HOL/NotAvailable?handle_bad=hein.journals/mlv37&collection=journals&index=journals/mlv&handle=hein.journals/mlv37&div=&id=639&page=&t=1561522205
dc.relation.ispartofpagefrom609
dc.relation.ispartofpageto616
dc.relation.ispartofissue4
dc.relation.ispartofjournalMedicine and Law
dc.relation.ispartofvolume37
dc.subject.fieldofresearchLaw
dc.subject.fieldofresearchcode1801
dc.titleJohn cunningham virus status and progressive multifocal leukoencephalopathy as material risks when treating relapsing remitting multiple sclerosis
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
dc.description.versionPost-print
gro.description.notepublicAfter all reasonable attempts to contact the copyright owner, this work was published in good faith in interests of the digital preservation of academic scholarship. Please contact copyright@griffith.edu.au with any questions or concerns.
gro.rights.copyright© 2018 World Association for Medical Law. The attached file is reproduced here in accordance with the copyright policy of the publisher. Use hypertext link to access the journal's website.
gro.hasfulltextFull Text
gro.griffith.authorBeran, Roy G.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record